Ilumya (tildrakizumab)

pCPA File Number: 21496

Negotiation Status:

Concluded with an LOI

Indication(s):

Psoriasis, moderate to severe plaque

Sponsor/Manufacturer:

Sun Pharma Canada Inc.

CADTH Project Number:

SR0624

pCPA Engagement Letter Issued:

2021-09-17

Negotiation Process Concluded:

2021-12-20